Strategic Investment Opportunity to engage Shilpa Medicare post-investment to accelerate clinical development and potentially expand into co-development or licensing discussions for lung therapeutics.

Collaborative Partnerships Leverage the 2023 BiomEdit collaboration to propose animal health and microbiome-driven strategies, exploring joint programs or advisory roles to expand pipeline applications and exploit cross-portfolio synergies.

Pulmonary Focus Highlight inhaled delivery advantages for distal lung targeting to position partnerships with contract manufacturing organizations, clinical service providers, and payer-ready pathways focused on IPF, COPD, and NCFBE.

Early Stage Advantage With preclinical live biotherapeutics and modest headcount, target biotech-focused investors, CROs, and platform licensors interested in scalable assets and reduced development risk profiles.

Funding Levers Use the current funding level (~$9M) and revenue range to craft financial models for potential co-funding, milestone-based deals, and grant-assisted studies to accelerate timelines and de-risk partnerships.